Jim Simons
KNSA icon

Jim Simons’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jim Simons’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-84,447
Closed -$1.19M – 3904
2023
Q2 		$1.19M Sell
84,447
-53,733
-39% -$719K ﹤0.01% 2364
2023
Q1 		$1.49M Buy
138,180
+71,480
+107% +$942K ﹤0.01% 2212
2022
Q4 		$999K Sell
66,700
-55,100
-45% -$802K ﹤0.01% 2531
2022
Q3 		$1.56M Buy
121,800
+67,800
+126% +$772K ﹤0.01% 2197
2022
Q2 		$523K Sell
54,000
-104,700
-66% -$977K ﹤0.01% 3140
2022
Q1 		$1.58M Sell
158,700
-144,600
-48% -$1.53M ﹤0.01% 2414
2021
Q4 		$3.57M Buy
+303,300
New +$3.73M ﹤0.01% 1745
2021
Q1 		– Sell
-16,700
Closed -$295K – 3525
2020
Q4 		$295K Buy
16,700
+1,000
+6% +$17.6K ﹤0.01% 3041
2020
Q3 		$241K Buy
+15,700
New +$295K ﹤0.01% 3064

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Jim Simons's KNSA Position: Q3 2023 in Review

Jim Simons sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2023, closing a stake of 84,447 shares — an estimated $1.19M sold.

Jim Simons first reported a position in KNSA in Q3 2020 and held it in 9 quarters. The position peaked at $3.57M in Q4 2021. 134 funds tracked by Wall St. Rank hold KNSA as of Q3 2023.

  • Jim Simons reported no remaining Kiniksa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Jim Simons sold 84,447 Kiniksa Pharmaceuticals shares in Q3 2023, an estimated $1.19M.
  • Jim Simons first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Jim Simons's Kiniksa Pharmaceuticals position peaked at $3.57M in Q4 2021.
  • 134 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.